Solid Q1 numbers, beat on both revenue and earnings, guiding for 15% EPS growth this year, and yet the stock went down. What am I missing that's brought the price down nearly 6 percent just in the last few days? I'd really like to know, because I'm... — read more
Good if niche choice
Let’s be clear from the start, Bruker never gets the spotlight afforded to much bigger life-science names, but the company has tech and research tools that give it a very defensible niche. The stock is often recognized by analysts but ignored by... — read more